Quantcast

Latest Rhinitis Stories

2008-10-29 12:00:07

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort(R) as the steroid comparator arm. A secondary efficacy...

2008-10-28 06:00:28

Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation. Anders Lonner, CEO of Meda, said: "This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation it could also mean better compliance for patients. The product would contribute...

2008-10-27 15:00:00

ANTONY, France, October 27 /PRNewswire-FirstCall/ -- Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults. The aim of the study, which will be conducted in 450 American patients during the 2009 pollen season, is to confirm the efficacy and good tolerance of the product in adults and to support the...

2008-10-17 03:00:16

Regulatory News: Meda AB (STO:MEDAA): The U.S. Food and Drug Administration (FDA) has approved Astepro - the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray. The active substance in these products is azelastine - the leading nasal antihistamine in the treatment of rhinitis in the U.S. Astepro is now approved for treatment of seasonal allergic rhinitis. Fewer reports...

2008-10-06 21:00:11

Thai researchers suggest patients on allergy medicine are better served when they adjust their dose to symptoms. The researchers found the effectiveness of intranasal corticosteroids -- a drug that reduces swelling and secretions in the nose -- could be achieved with three-quarters of the usually recommended daily dosage when patients were instructed how to vary the daily dosage in response to severity of symptoms. This new approach to dosing could help prevent the problem of increased...

2008-10-03 09:00:38

Circassia, a specialty biopharmaceutical company, has started a further Phase II clinical study of its ToleroMune technology in the field of cat allergy. The trial builds on positive results achieved in an earlier Phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous Phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune...

2008-10-02 06:00:34

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous phase II clinical trial,...

2008-09-26 12:00:35

Breathe Again(TM), Europe's best selling hypertonic saline nasal spray, is now available in the United States. Clinically tested in France, Breathe Again (www.breatheagain.us) is 100% natural, combining the benefits of pure seawater and the drying effect of a hypertonic solution. Harvested from Europe's purest tidal seawater off the coast of Saint Malo, France, the superior and unique nasal spray can be used for allergy prevention, nasal congestion, sinus problems and nasal hygiene. With...

2008-09-24 12:00:37

Sanofi-Aventis has announced that the FDA has approved Nasacort AQ nasal spray for children aged two to five years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively to treat nasal symptoms of year-round allergies in children between two and five years. This is said...

2008-09-24 06:00:00

Nasacort, a nasal steroid used in allergic rhinitis, has been approved for the treatment of children aged two to five years old. Although the breadth of its label is now similar to that of some of its competitors, Datamonitor does not expect that the expanded approval will have a significant impact on sales. Sanofi-Aventis has announced that the FDA has approved the use of Nasacort nasal spray (triamcinolone), the company's treatment of nasal symptoms associated with seasonal and perennial...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'